Jiang Wenxin, Yu Xiao-Dong, Deng Yanqing
Wenxin Jiang, Department of Neurology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Xiao-dong Yu, Department of Neurology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Pak J Med Sci. 2023 Mar-Apr;39(2):485-490. doi: 10.12669/pjms.39.2.6901.
To evaluate the effect of butylphthalide combined with oxiracetam on cognitive function, intellectual recovery and serum inflammatory factors in patients with cognitive impairment after cerebral infarction.
This is a Clinical comparative study. A total of 80 patients with cognitive impairment after cerebral infarction who visited Renmin Hospital, Hubei University of Medicine from January 2020 to January 2022 were enrolled and randomly divided into two groups. Patients in the control group were treated with oral oxiracetam combined with routine treatment. Patients in the study group were given butylphthalide combined with oxiracetam on the basis of routine treatment. Compare the clinical effect, cognitive function and intellectual recovery, inflammatory factor level changes, CBV, CBF, MTT and other cerebral blood flow perfusion indicators, as well as post-treatment incidence of adverse drug reactions in the two groups of patients.
The efficacy of the study group was significantly higher than that of the control group (p=0.03). After treatment, the levels of CBV and CBF in the study group were higher than those in the control group, the levels of TNF-α, CRP and IL-6 were significantly lower than those of the control group, while MTT was shorter than that in the control group, with statistically significant difference (p=0.00). Furthermore, there was a statistically significant difference that the MMSE score and MOCA score of the study group were higher than those of the control group (p=0.00).
Butylphthalide combined with oxiracetam has an obvious curative effect in the treatment of patients with cognitive impairment after cerebral infarction. It is a safe and effective therapeutic option that can significantly recover cognitive function and intelligence, improve cerebral blood flow perfusion and reduce inflammatory factors, without an obvious increase in adverse reactions.
评估丁苯酞联合奥拉西坦对脑梗死认知功能障碍患者认知功能、智力恢复及血清炎症因子的影响。
这是一项临床对照研究。选取2020年1月至2022年1月在湖北医药学院附属人民医院就诊的80例脑梗死认知功能障碍患者，随机分为两组。对照组患者采用口服奥拉西坦联合常规治疗。研究组患者在常规治疗基础上给予丁苯酞联合奥拉西坦。比较两组患者的临床疗效、认知功能和智力恢复情况、炎症因子水平变化、脑血容量（CBV）、脑血流量（CBF）、平均通过时间（MTT）等脑血流灌注指标，以及治疗后药物不良反应发生率。
研究组疗效显著高于对照组（p = 0.03）。治疗后，研究组CBV和CBF水平高于对照组，肿瘤坏死因子-α（TNF-α）、C反应蛋白（CRP）和白细胞介素-6（IL-6）水平显著低于对照组，而MTT短于对照组，差异有统计学意义（p = 0.00）。此外，研究组简易精神状态检查表（MMSE）评分和蒙特利尔认知评估量表（MOCA）评分高于对照组，差异有统计学意义（p = 0.00）。
丁苯酞联合奥拉西坦治疗脑梗死认知功能障碍患者有明显疗效。它是一种安全有效的治疗选择，可显著恢复认知功能和智力，改善脑血流灌注并降低炎症因子水平，且不良反应无明显增加。
